It arrives on a schedule. Somewhere in the week or two before menstruation, the floor drops out. Anger with no clear object. Tears and heightened sensitivity toward things that you wouldn’t normally bat an eyelash at. A conviction that the life you have built is the wrong one. Then the bleeding starts, and within a day or two the fog lifts, and the person you recognize walks back in.
That pattern has a name, a set of diagnostic criteria, and a growing body of research behind it. Most women who live with it spend years not knowing that.
What PMDD is
Premenstrual dysphoric disorder (PMDD) is a cyclical depressive disorder tied to the hormonal shifts of the menstrual cycle. It produces emotional, physical, and behavioral symptoms severe enough to interfere with work, school, and relationships. Symptoms start in the luteal phase, which is the second half of the menstrual cycle, following ovulation. When menstruation (the menstrual bleed) begins, symptoms then diminish. PMDD can affect anyone who ovulates, which includes transgender men and nonbinary people who menstruate.
PMDD is not caused by abnormal hormone levels, rather it is thought to be due to a heightened sensitivity to the normal hormonal fluctuations that occur in the luteal phase. Hypotheses on why symptoms occur point specifically to a sensitivity to the rise and fall of estrogen and progesterone across the cycle, with downstream effects on neurotransmitters serotonin and GABA, calcium regulation, and inflammatory pathways.
PMDD did not become a standalone diagnosis in the Diagnostic and Statistical Manual of Mental Disorders (DSM) until 2013. That recency can explain part of the reason why it remains so poorly recognized. However, we need more PMDD specific research, more comprehensive training for medical providers and practitioners on PMDD, and more education on the menstrual cycle in high schools so that those with a cycle understand their body and can more readily identify what is not normal.
PMDD is not PMS
Premenstrual syndrome (PMS) and PMDD share a symptom vocabulary, which is part of the confusion. PMS requires at least one emotional, physical, or behavioral symptom that worsens in the luteal phase and resolves once menstruation begins. Between 20% and 30% of women with premenstrual symptoms meet criteria for PMS. While it is difficult to pinpoint the exact incidence and prevalence of PMDD, some estimates show that 5.5% of menstruating women meet full diagnostic criteria for PMDD.
The functional impairment of PMDD sits well beyond that of PMS. Diagnosis requires at least five symptoms present in most cycles, with at least one being a mood symptom: labile affect, irritability or anger, depressed mood or hopelessness, or anxiety and tension. Additional symptoms may include loss of interest, difficulty concentrating, fatigue, appetite or sleep changes, and physical symptoms such as breast tenderness, bloating, or pain. The symptoms must cause real distress and interfere with daily functioning, and they must ease within days of menstruation beginning and disappear after it ends.
Other explanations have to be ruled out first, including thyroid conditions, substance or medication effects, and the possibility that what is happening is a premenstrual worsening of a condition that is already present year-round. That distinction has a name of its own, premenstrual exacerbation, and it matters clinically. PMDD is defined by the fact that symptoms lift shortly after the bleed begins.
Why diagnosis takes so long
On average, a woman with PMDD can wait twelve years and see as many as six healthcare providers before receiving an accurate diagnosis.
Several forces compound each other.
Symptom overlap. PMDD frequently occurs alongside anxiety disorders, ADHD, and PTSD, and it can be mistaken for any of them. Polyendocrine metabolic ovarian syndrome (PMOS), the condition renamed from polycystic ovary syndrome (PCOS) in 2026, carries its own complex relationship with premenstrual disorders.
Screening that does not happen. Menstrual health remains under-discussed in clinical settings. Patients who have never talked about menstruation with a clinician may not know what is healthy, and may assume an abnormal experience is simply normal.
Dismissal. Reported symptoms are sometimes minimized without evaluation. The term for this in the literature is medical gaslighting, defined as invalidating a patient's genuine clinical concern without proper medical evaluation, whether due to ignorance, implicit bias, or paternalism.
Cultural inheritance. In many cultures menstruation is treated as private, shameful, or a form of suffering to be quietly absorbed. That framing teaches women to minimize even severe symptoms.
What to do
Start by tracking your cycle
Diagnosis cannot be made from memory. Confirmation requires daily ratings across at least two symptomatic cycles, because retrospective recall is unreliable and can lead to misdiagnosis. You do not need an app, a smart ring, or a subscription. A calendar, a planner, or a sheet of paper on your nightstand will do.
Begin with the basics: when your period starts, when it ends, how you feel in the week before, and how you feel once bleeding begins. More detail is better.
Log the date, your mood, irritability level, energy, sleep, appetite, physical symptoms, and anything happening in your relationships/work, etc. Over a series of menstrual cycles, a pattern either emerges or it does not, and both answers are useful.
Practitioners use clinical instruments for screening and tracking symptoms. The Daily Record of Severity of Problems (DRSP) is the daily log often used to clinically confirm the diagnosis.
Bring the paper with you
Take your log (and a list of questions) to your appointment, whether that is with a primary care provider, a gynecologist, psychiatrist, or psychiatric mental health nurse practitioner.
Medical visits move fast. It is hard to summarize months of your life in twelve minutes while someone types. Bringing notes with you allows your visit to work harder for you, and that is true of any health concern, menstrual or otherwise.
What can help
The foundations
Prioritize sleep, proper nutrition, movement, and stress-reducing techniques. While not a cure, they are incredibly impactful for mood, hormone balance, and brain health. Get outside and be in nature. Walk daily. Increase movement as your body tolerates it, whether that means longer walks, stretching, yoga, dancing, or building toward cardio and strength work. Consider paced breathing exercises (4 second inhale, 6 second exhale), progressive muscle relaxation, or yoga nidra.
Before adding anything to your diet, consider what might be removed. Ultra-processed food, excess sugar, caffeine, alcohol, nicotine, and cannabis/THC all deserve an honest audit. Notice how much you are consuming, and where a reduction (or elimination) might be possible.
Therapy
Cognitive behavioral therapy (CBT) is strongly recommended for PMDD. It can help you identify unhelpful thought patterns and to change the behaviors attached to them.
Dialectical behavior therapy (DBT) is newer to this space. A treatment model tailored to PMDD has been proposed, moving through DBT modules of mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness.
Medication
Three medications from the selective serotonin reuptake inhibitor (SSRI) drug class have FDA approval in the US for PMDD: sertraline, paroxetine, and fluoxetine. They are considered a first-line treatment and are included in current clinical guidance.
A detail worth knowing before your appointment: SSRIs work differently for PMDD than for depression. In major depression, effects can take weeks. In PMDD, benefit is sometimes observed within days. Because of that, they can be prescribed continuously OR intermittently, meaning taken only during the luteal phase in the ten to fourteen days before menstruation. Intermittent dosing may be associated with fewer side effects.
If you want to explore medication, ask for an appointment with a primary care provider, psychiatrist, or psychiatric mental health nurse practitioner (PMHNP). This is separate from working with a therapist, who cannot prescribe medication.
SSRIs can come with unwanted side effects and do not work for everyone. However, some do see a positive response. A gynecology referral can also be necessary for education and resources about additional hormonal treatment options, especially for severe PMDD.
Herbs and supplements
Before we get into recommendations out there, we want to highlight safety first. It is not recommended to begin any new supplement without speaking to your healthcare provider. Even ordinary nutritional or herbal supplements can interact with medications or produce unexpected effects, particularly when taken daily or in large amounts. While this is not meant to frighten, we encourage you to first be informed before you take anything. As a rule, research the brand, check interactions and side effects, and raise it with your provider first.
Look for third-party tested supplements. In the United States, supplements are not reviewed by the FDA for safety or effectiveness before they reach the shelf the way medications are, and third-party testing helps confirm that what is on the label is what is in the bottle.
Saffron is an herb that has been used as a medicinal agent for centuries. Saffron has been used in traditional healing as an antidepressant and stimulant and also has anxiolytic, anti-inflammatory, antioxidant, analgesic, and aphrodisiac properties. Newer research shows positive effects of saffron for PMS and PMDD.
Calcium is a mineral that is essential for female bone density and is involved in neurotransmitter regulation. Serum calcium tends to fluctuate with changes in estrogen, meaning changes in the luteal phase can also affect serum calcium level. Women with PMS tend to have lower serum calcium than women without PMS.
Omega-3 fatty acids can lower inflammatory factors and have benefits for cardiovascular health, insulin resistance, and brain health. It is believed that the anti-inflammatory mechanism may contribute to psychological and antidepressant effects. Inflammation contributes to premenstrual symptoms, so omega-3 fatty acids may contribute to the reduction of some PMS and PMDD symptoms as well.
Vitamin B6 is a water-soluble vitamin involved in many processes pertinent to mental health and PMDD. B6 plays a role in neurotransmitter metabolism and is a cofactor in the synthesis of serotonin from tryptophan. It has shown evidence for emotional symptoms in PMS.
Vitex, also called chasteberry, is an herb from the fruit of a shrub which has shown positive benefits for premenstrual symptoms such as bloating, breast tenderness, and irritability.
Curcumin is the active compound in turmeric, which is in the same plant family as ginger. Curcumin is known to have a range of benefits such as being anti-inflammatory, immuno-modulatory, and an antioxidant. It has been used in cardiovascular, neurological, and autoimmune diseases. Evidence continues to grow on its benefits for brain health, depression, and PMS.
A caution underneath all of this: research on PMDD is thin. Many studies on these complementary therapies were conducted in individuals with PMS or general depressive symptoms rather than diagnosed PMDD, and many studies on PMS and PMDD have had small samples and short trial durations. That is a funding problem more than an official verdict on the therapies themselves.
If your providers are not sure how to advise you on nutritional or herbal approaches, seek counseling from a licensed nutritionist, an integrative or functional health provider, or a naturopathic physician. Herbalists, Traditional Chinese Medicine (TCM) doctors, and acupuncturists may also be able to provide guidance for premenstrual symptoms. Look at their education, their licenses, and reviews to see if they can be a trusted resource for you.
We provide this info not as medical or prescriptive advice. We simply want you to know that if you are suffering from PMDD now, there is hope. There are additional options that a conventional medicine provider may not readily review with you. We hope to help raise awareness of PMDD and safe methods to alleviate its symptoms.
If you are struggling right now
Suicidal thoughts are common in PMDD, particularly in the luteal phase. That is not included here to alarm anyone, but for you to know that if you are experiencing it, you are not alone.
If you or someone you know is having thoughts of harming themselves (or others), please tell someone. A trusted friend, a partner, a family member is a place to start. In the United States, you can call or text 988 to reach the Suicide and Crisis Lifeline at any hour.
Start looking for a therapist today. Not all therapists are equally suited to what you are carrying. Specialties differ, and so does fit. Finding the right person can take time, and it is worth having someone you feel safe telling your truth to. If the search itself feels like too much, ask someone you trust to help make the first calls.
Whatever you are dealing with, you are not alone in it, and there is reason for hope even when you cannot feel it. The first step is asking for help, or simply writing down what you are experiencing so that you can begin to understand it yourself.
More resources
International Association for Premenstrual Disorders (IAPMD) Global resource for premenstrual dysphoric disorder and premenstrual exacerbation.
Pushing Past PMDD Founded in 2019 by Madison Ashworth, a PMDD warrior and advocate, now a 501(c)(3) nonprofit providing education and resources for PMDD.
Psychology Today Therapist directory searchable by insurance and specialty.
988 Suicide and Crisis Lifeline Free support for anyone in crisis or emotional distress, 24 hours a day, across the United States and its territories, connecting a national network of local crisis centers.
Sources:
American College of Obstetricians and Gynecologists. (2023). Management of premenstrual disorders: ACOG clinical practice guideline no. 7. Obstetrics and Gynecology, 142(6), 1516–1533. https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/12/management-of-premenstrual-disorders
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
Buys, M. E. (2025). Psychotherapy modalities for premenstrual change: A systematic review. Women & Therapy, 49(1), 31–68. https://doi.org/10.1080/02703149.2025.2534636
Casola, A. R., Renaud, A., & Mulki, A. K. (2024). Discussing menstrual health in family medicine. Family Medicine and Community Health, 12(2). https://doi.org/10.1136/fmch-2023-002149
Cerqueira, R. O., Frey, B. N., Leclerc, E., & Brietzke, E. (2017). Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: A systematic review. Archives of Women's Mental Health, 20, 713–719. https://doi.org/10.1007/s00737-017-0791-0
Cheng, Y. C., Huang, W. L., Chen, W. Y., Huang, Y. C., Kuo, P. H., & Tu, Y. K. (2025). Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis. Psychological Medicine, 55. https://doi.org/10.1017/S0033291725000996
Eisenlohr-Moul, T., Divine, M., Schmalenberger, K., Murphy, L., Buchert, B., Wagner-Schuman, M., Kania, A., Raja, S., Miller, A. B., Barone, J., & Ross, J. (2022). Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with premenstrual dysphoric disorder. BMC Psychiatry, 22(1), 199. https://pmc.ncbi.nlm.nih.gov/articles/PMC8933886/
Ilcioglu, K., Yıldırım Bayraktar, B., & Demirhan Kayacık, A. (2025). The effect of calcium on premenstrual syndrome: A meta-analysis study. Journal of Clinical Medicine of Kazakhstan, 22(1), 42–48. https://doi.org/10.23950/jcmk/15827
Jespersen, C., Lauritsen, M. P., Frokjaer, V. G., & Schroll, J. B. (2024). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. The Cochrane Database of Systematic Reviews, 8(8). https://doi.org/10.1002/14651858.CD001396.pub4
Mohammadi, M. M., Dehghan Nayeri, N., Mashhadi, M., & Varaei, S. (2022). Effect of omega-3 fatty acids on premenstrual syndrome: A systematic review and meta-analysis. The Journal of Obstetrics and Gynaecology Research, 48(6), 1293–1305. https://doi.org/10.1111/jog.15217
Mohammadi, M. M., & Karimi, Z. (2026). Effect of saffron on premenstrual syndrome and dysmenorrhea: A systematic review and meta-analysis. Korean Journal of Family Medicine, 47(1), 69–80. https://doi.org/10.4082/kjfm.24.0259
Moss, C. F., Chinna-Meyyappan, A., Skovronsky, G., Holloway, J., Lorenzini, S., Muhammad, N., Kopits, I., Perelmuter, S., Mitchell, L., Rief, M., Krapf, J., Pukall, C., & Goldstein, A. (2025). Experiences of care and gaslighting in patients with vulvovaginal disorders. JAMA Network Open, 8(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC12062909/
Oliveri, A., Muir, S., Mu, E., & Kulkarni, J. (2025). Advancing psychological interventions for premenstrual dysphoric disorder: A dialectical behaviour therapy-informed treatment model. The Australian and New Zealand Journal of Psychiatry, 59(8), 670–673. https://doi.org/10.1177/00048674251348370
Opatowski, M., Deng, J., Yang, Q., Oberg, A. S., Cesta, C. E., & Lu, D. (2025). Polycystic ovary syndrome and the risk of premenstrual disorders: A nationwide register-based study in Sweden. Depression and Anxiety, 2025, 8226088. https://doi.org/10.1155/da/8226088
Prasad, D., Wollenhaupt-Aguiar, B., Kidd, K. N., de Azevedo Cardoso, T., & Frey, B. N. (2021). Suicidal risk in women with premenstrual syndrome and premenstrual dysphoric disorder: A systematic review and meta-analysis. Journal of Women's Health, 30(12), 1693–1707. https://doi.org/10.1089/jwh.2021.0185
Rajabi, F., Rahimi, M., Sharbafchizadeh, M. R., & Tarrahi, M. J. (2020). Saffron for the management of premenstrual dysphoric disorder: A randomized controlled trial. Advanced Biomedical Research, 9, 60. https://doi.org/10.4103/abr.abr_49_20
Robinson, J., Ferreira, A., Iacovou, M., & Kellow, N. J. (2025). Effect of nutritional interventions on the psychological symptoms of premenstrual syndrome in women of reproductive age: A systematic review of randomized controlled trials. Nutrition Reviews, 83(2), 280–306. https://doi.org/10.1093/nutrit/nuae043
Shrateh, O. N., Jawed, A., Shuja, M. H., Kumar, K. A., Rehan, S. T., Abdelrhman, S., Naasan, M., & Wahab, N. A. A. (2025). Curcumin, a bioactive supplement for premenstrual syndrome and dysmenorrhea: A systematic review of randomised clinical trials. European Journal of Obstetrics & Gynecology and Reproductive Biology, 28. https://doi.org/10.1016/j.eurox.2025.100432
Verkaik, S., Kamperman, A. M., van Westrhenen, R., & Schulte, P. F. J. (2017). The treatment of premenstrual syndrome with preparations of vitex agnus castus: A systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 217(2), 150–166. https://doi.org/10.1016/j.ajog.2017.02.028
Wang, Z., Zhang, Q., Huang, H., & Liu, Z. (2021). The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders, 282, 242–251. https://doi.org/10.1016/j.jad.2020.12.158